SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is soaring after pre-announcing preliminary Q3 revenue well above expectations and reiterating robust fiscal year growth, fueling strong community belief that the AI data center infrastructure play was significantly undervalued amid massive hyperscaler capital expenditure. Traders are actively discussing the stock's sharp rebound and its potential for continued upside as a key beneficiary of the ongoing AI buildout.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is seeing significant trending activity with its community actively working to "drop a zero" from its price, driven by excitement over its AI-powered utility, new exchange listings, and ecosystem expansion on the Base chain. Community members are enthusiastically accumulating, citing its undervalued market cap and growing revenue, even amid broader crypto market volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending following a drastic stock plunge driven by the abrupt departure of its CFO and general counsel, an SEC investigation into cash management, and an accounting review exposing internal control weaknesses and revised future guidance, sparking intense community debate between those foreseeing catastrophe and others viewing it as an extreme overreaction and buying opportunity.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's issuance of a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns with trial design and the appropriateness of its surrogate endpoint. The community is actively debating the broader implications for gene therapies, RGNX's financial outlook, and potential impacts on its Duchenne and AbbVie-partnered programs.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

MSLE is actively discussed following its recent NASDAQ listing, a reverse split, and a substantial equity raise. While optimists view the financing as a strong vote of confidence in its "revolutionary" muscle regeneration drug for Duchenne patients and foresee potential acquisition, skeptics caution about dilution and characterize early clinical data as premature hype.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is seeing significant conversation after its CEO signaled multi-year highs in mortgage loan production and gain-on-sale performance, leading to community debate on whether its integrated platform can overcome broader housing market headwinds amidst ongoing institutional accumulation.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health (OSCR) is trending sharply higher after the House passed a bill to extend ACA subsidies, fueling investor optimism for significant upside and a potential short squeeze, though community debate persists on the bill's Senate fate and the company's path to profitability ahead of its upcoming earnings.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending as its S-4 registration for the Infleqtion merger is effective, with a shareholder vote scheduled for February 12 and a ticker change to INFQ expected by February 17. The community actively debates Infleqtion's perceived undervaluation compared to quantum peers, highlighting its neutral-atom technology, existing revenue, and strategic partnerships with government agencies and NVIDIA, while also discussing recent volatility and concerns about potential post-merger dilution.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed as the community awaits crucial R2 SUV details and earnings, with its CEO emphasizing the R2's cost-efficient design and potential to significantly boost profitability, though investor sentiment remains divided on its market impact and the company's cash burn amid EV sector competition.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing extreme volatility following a patent infringement lawsuit from Novo Nordisk and FDA scrutiny regarding its compounded semaglutide weight-loss pill, which the company has now ceased offering. The community is fiercely debating whether this represents a fundamental threat and further downside, or an overreaction presenting a significant short squeeze opportunity for a company with strong core business segments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?

BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.

Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data

PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.

Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?

BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.

Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX

Lingohr Asset Management GmbH boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 598.4% during the 3rd quarter, according to its most recent 13F filing with...

Will BMY's Oncology Collaborations Drive Its Next Growth Phase?

BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.

Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?

PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates weigh on the outlook

BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa

Lbp Am Sa raised its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 15.7% during the 3rd quarter, according to the company in its most recent 13F filing with the...

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen analysts that are presently covering the firm, MarketBeat reports. One...

Sector Gamma AS Has $2.74 Million Holdings in BioNTech SE Sponsored ADR $BNTX

Sector Gamma AS trimmed its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 26.0% during the third quarter, according to its most recent 13F filing with the SEC. The...

BioNTech (NASDAQ:BNTX) Earns Buy Rating from Berenberg Bank

Berenberg Bank restated a "buy" rating on shares of BioNTech in a research report on Friday...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$110.34
Prev Close	$106.62
Open	$106.86
Dividend Yield	0.00%
50-Day Moving Average	$101.90
Beta	0.84
Avg. Volume	1.06M
PE Ratio	-40.55

52-Week High	$124.49
52-Week Low	$81.20
Market Capitalization	$25.64B
EPS (Annual)	-$2.99
Price to Book	1.18
Revenue Per Employee	$439,432.88
Enterprise Value/EBITDA	N/A

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTXBioNTech SE - ADR